CD44 and ovarian carcinoma: Evaluation of the expression of solCD44std, solCD44v5, and solCD44v6 in ovarian cancer through both IHC and serological analyses suggested that CD44 splice variants are expressed at low levels in malignant ovarian tumors and that their serum levels do not reliably reflect the tumor burden [37].